Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

Core Insights - Zymeworks Inc. has appointed Leone Patterson as Executive Vice President and Chief Business and Financial Officer, effective September 1, 2024, to support the company's growth and development [1][6][10] Company Overview - Zymeworks is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving care for difficult-to-treat diseases, particularly cancers [4] - The company has a proprietary technology called Azymetric™, which is used to engineer and develop antibody-based therapeutic candidates, including zanidatamab, a HER2-targeted bispecific antibody [4] Leadership and Experience - Leone Patterson brings over 20 years of experience in the biotech sector, having held leadership roles in various companies, including Tenaya Therapeutics and Adverum Biotechnologies [3][6] - Patterson's responsibilities will include developing Zymeworks' long-term financial strategy and supporting strategic business decisions [10] Pipeline and Development Goals - Zymeworks aims to achieve its '5 by 5' goal, which includes having five novel antibody-drug conjugates or T cell engagers in clinical studies by 2026 [6] - The company is advancing zanidatamab through multiple global clinical trials and has submitted a Biologics License Application (BLA) to the FDA for accelerated approval for biliary tract cancer [4][6]